1,897 results match your criteria Nature Reviews Rheumatology[Journal]


Insights into rheumatic diseases from next-generation sequencing.

Nat Rev Rheumatol 2019 Apr 18. Epub 2019 Apr 18.

Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, USA.

Rheumatic diseases have complex aetiologies that are not fully understood, which makes the study of pathogenic mechanisms in these diseases a challenge for researchers. Next-generation sequencing (NGS) and related omics technologies, such as transcriptomics, epigenomics and genomics, provide an unprecedented genome-wide view of gene expression, environmentally responsive epigenetic changes and genetic variation. The integrated application of NGS technologies to samples from carefully phenotyped clinical cohorts of patients has the potential to solve remaining mysteries in the pathogenesis of several rheumatic diseases, to identify new therapeutic targets and to underpin a precision medicine approach to the diagnosis and treatment of rheumatic diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0217-7DOI Listing

Has lupus anticoagulant testing had its day?

Nat Rev Rheumatol 2019 Apr 18. Epub 2019 Apr 18.

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0218-6DOI Listing

B cell checkpoints in autoimmune rheumatic diseases.

Nat Rev Rheumatol 2019 Apr 9. Epub 2019 Apr 9.

Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.

B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen-presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0211-0DOI Listing

Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.

Nat Rev Rheumatol 2019 Apr 5. Epub 2019 Apr 5.

Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland.

Systemic sclerosis (SSc) is an autoimmune fibrotic disease of unknown aetiology that is characterized by vascular changes in the skin and visceral organs. Autologous haematopoietic stem cell transplantation can improve skin and organ fibrosis in patients with progressive disease and a high risk of organ failure, indicating that cells originating in the bone marrow are important contributors to the pathogenesis of SSc. Animal studies also indicate a pivotal function of myeloid cells in the development of fibrosis leading to changes in the tissue architecture and dysfunction in multiple organs such as the heart, lungs, liver and kidney. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0212-zDOI Listing

Spontaneous dog osteoarthritis - a One Medicine vision.

Nat Rev Rheumatol 2019 Apr 5. Epub 2019 Apr 5.

Skeletal Biology Group, Comparative Biomedical Sciences, Royal Veterinary College, University of London, London, UK.

Osteoarthritis (OA) is a global disease that, despite extensive research, has limited treatment options. Pet dogs share both an environment and lifestyle attributes with their owners, and a growing awareness is developing in the public and among researchers that One Medicine, the mutual co-study of animals and humans, could be beneficial for both humans and dogs. To that end, this Review highlights research opportunities afforded by studying dogs with spontaneous OA, with a view to sharing this active area of veterinary research with new audiences. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41584-019-0202-1
Publisher Site
http://dx.doi.org/10.1038/s41584-019-0202-1DOI Listing
April 2019
8 Reads

CAR T cells drive out B cells in SLE.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Apr 4. Epub 2019 Apr 4.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0214-xDOI Listing
April 2019
1 Read

Bone inflamm-ageing.

Nat Rev Rheumatol 2019 Apr 4. Epub 2019 Apr 4.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0216-8DOI Listing
April 2019
1 Read

Blocking CD40-CD40L interactions in Sjögren syndrome.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Apr 3. Epub 2019 Apr 3.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0215-9DOI Listing
April 2019
1 Read

NGF vaccine reduces pain.

Nat Rev Rheumatol 2019 Mar 28. Epub 2019 Mar 28.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0213-yDOI Listing

New species of gut bacteria associated with AS.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar 27. Epub 2019 Mar 27.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0209-7DOI Listing

Recombinant IL-1Ra as first-line therapy in sJIA.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar 27. Epub 2019 Mar 27.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0208-8DOI Listing

Aspirin meets cGAS.

Authors:
Keith B Elkon

Nat Rev Rheumatol 2019 Mar 26. Epub 2019 Mar 26.

Departments of Medicine and Immunology, University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0205-yDOI Listing

Targeting NF-κB in tendinopathy.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Mar 26. Epub 2019 Mar 26.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0206-xDOI Listing
March 2019
1 Read

Serum biomarkers of disease activity in JDM.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar 26. Epub 2019 Mar 26.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0210-1DOI Listing

IVIG and ciclosporin for Kawasaki disease.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar 26. Epub 2019 Mar 26.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0207-9DOI Listing
March 2019
1 Read

Cholesterol and cartilage do not mix well.

Authors:
Frank Beier

Nat Rev Rheumatol 2019 Mar 26. Epub 2019 Mar 26.

Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Western Bone and Joint Institute, Western University, London, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0204-zDOI Listing

Tapering bDMARDs in axial SpA - what is the current evidence?

Nat Rev Rheumatol 2019 Mar 22. Epub 2019 Mar 22.

Ruhr-University Bochum, Bochum, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0201-2DOI Listing

Bacterial cell wall offcasts linked to autoimmune disease.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar 20. Epub 2019 Mar 20.

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0203-0DOI Listing

mTORC1 promotes pathological bone-cartilage interplay.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Apr;15(4):190

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0200-3DOI Listing

Inclusion body myositis: clinical features and pathogenesis.

Nat Rev Rheumatol 2019 Mar 5. Epub 2019 Mar 5.

Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.

Inclusion body myositis (IBM) is often viewed as an enigmatic disease with uncertain pathogenic mechanisms and confusion around diagnosis, classification and prospects for treatment. Its clinical features (finger flexor and quadriceps weakness) and pathological features (invasion of myofibres by cytotoxic T cells) are unique among muscle diseases. Although IBM T cell autoimmunity has long been recognized, enormous attention has been focused for decades on several biomarkers of myofibre protein aggregates, which are present in <1% of myofibres in patients with IBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0186-xDOI Listing
March 2019
5 Reads

Cholesterol test for T cells.

Nat Rev Rheumatol 2019 Apr;15(4):189

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0195-9DOI Listing
April 2019
3 Reads

Oncogenes and inflammasomes in lupus nephritis.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Apr;15(4):190

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0194-xDOI Listing
April 2019
4 Reads

Gut microbiota changes pre-date onset of RA.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Apr;15(4):188

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0198-6DOI Listing

No need for DMARD holiday before arthroplasty.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Apr;15(4):188

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0199-5DOI Listing
April 2019
2 Reads

Tocilizumab improves quality of life in GCA.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Apr;15(4):188

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0197-7DOI Listing
April 2019
2 Reads

Gut microbiota linked to kidney disease in SLE.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Apr;15(4):188

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0196-8DOI Listing
April 2019
1 Read

AMPK: a therapeutic target in RA?

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Apr;15(4):188

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0192-zDOI Listing
April 2019
2 Reads

Platelets: emerging facilitators of cellular crosstalk in rheumatoid arthritis.

Nat Rev Rheumatol 2019 Apr;15(4):237-248

Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa.

Rheumatoid arthritis (RA) is an autoimmune disease in which a variety of circulating pro-inflammatory cells and dysregulated molecules are involved in disease aetiology and progression. Platelets are an important cellular element in the circulation that can bind several dysregulated molecules (such as collagen, thrombin and fibrinogen) that are present both in the synovium and the circulation of patients with RA. Platelets not only respond to dysregulated molecules in their environment but also transport and express their own inflammatory mediators, and serve as regulators at the boundary between haemostasis and immunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0187-9DOI Listing
April 2019
1 Read

Glucocorticoid response mapped.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Apr;15(4):189

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0191-0DOI Listing
April 2019
1 Read

Advances in antibody engineering for rheumatic diseases.

Nat Rev Rheumatol 2019 Apr;15(4):197-207

Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland.

The advent of biologic therapies, particularly antibody therapeutics, has revolutionized the pharmacological treatment of many rheumatic diseases. Antibody discovery began with the immunization of mice for the production of rodent immunoglobulins, but advances in protein and genetic engineering have now made it possible to generate fully human antibodies, which are better tolerated by patients. For most clinical applications in rheumatology, antibodies have been used as blocking agents capable of neutralizing the function of pro-inflammatory proteins, such as TNF. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41584-019-0188-8
Publisher Site
http://dx.doi.org/10.1038/s41584-019-0188-8DOI Listing
April 2019
1 Read

PU.1 pulls the strings in fibrotic disease.

Nat Rev Rheumatol 2019 Apr;15(4):187

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0193-yDOI Listing
April 2019
2 Reads

Measuring disease activity in SLE is an ongoing struggle.

Nat Rev Rheumatol 2019 Apr;15(4):194-195

Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0190-1DOI Listing

Emerging targets of disease-modifying therapy for systemic sclerosis.

Nat Rev Rheumatol 2019 Apr;15(4):208-224

Scleroderma Program, Departments of Medicine, Dermatology and Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Systemic sclerosis (SSc) has the highest cause-specific mortality of all the connective tissue diseases, and the aetiology of this complex and heterogeneous condition remains an enigma. Current disease-modifying therapies for SSc predominantly target inflammatory and vascular pathways but have variable and unpredictable clinical efficacy, and none is curative. Moreover, many of these therapies possess undesirable safety profiles and have no appreciable effect on long-term mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0184-zDOI Listing

Could IL-6 inhibition prevent exercise-induced fat loss in RA?

Nat Rev Rheumatol 2019 Apr;15(4):192-194

Clinical Research Unit, Russells Hall Hospital, Dudley Hospitals NHS Foundation Trust, Dudley, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0189-7DOI Listing

Anti-IL-1 for the treatment of OA: dead or alive?

Nat Rev Rheumatol 2019 Apr;15(4):191-192

Department of Rheumatology, Hospital Henri Mondor, UPEC Paris XII, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0185-yDOI Listing

Antiresorptive and anabolic agents in the prevention and reversal of bone fragility.

Nat Rev Rheumatol 2019 Apr;15(4):225-236

Department of Medicine and St Vincent's Institute, University of Melbourne, Melbourne, Victoria, Australia.

Bone volume, microstructure and its material composition are maintained by bone remodelling, a cellular activity carried out by bone multicellular units (BMUs). BMUs are focally transient teams of osteoclasts and osteoblasts that respectively resorb a volume of old bone and then deposit an equal volume of new bone at the same location. Around the time of menopause, bone remodelling becomes unbalanced and rapid, and an increased number of BMUs deposit less bone than they resorb, resulting in bone loss, a reduction in bone volume and microstructural deterioration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0172-3DOI Listing

Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.

Nat Rev Rheumatol 2019 Mar;15(3):153-166

Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Psoriasis is one of the most common chronic inflammatory skin diseases, affecting 3% of the world's population, and approximately one-third of patients with psoriasis will eventually transition to having psoriatic arthritis (PsA). The evolution from cutaneous to synovio-entheseal inflammation in these patients presents an opportunity to investigate the critical events linked to arthritis development. The events responsible for progression to PsA are currently unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0175-0DOI Listing
March 2019
1 Read

Disease modification in OA - will we ever get there?

Nat Rev Rheumatol 2019 Mar;15(3):133-135

Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0174-1DOI Listing

Calculating TNF dynamics.

Nat Rev Rheumatol 2019 Mar;15(3):128

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0183-0DOI Listing

Defective T cell checkpoint in SLE.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar;15(3):125

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0182-1DOI Listing
March 2019
3 Reads

Sensing bone mass.

Nat Rev Rheumatol 2019 Mar;15(3):128

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0181-2DOI Listing

OA genetic risk loci more than doubled.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Mar;15(3):126

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0179-9DOI Listing

Assisted reproduction less effective in RA.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Mar;15(3):126

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0178-xDOI Listing

Lung biomarkers in SSc: prognostic or diagnostic?

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Mar;15(3):126

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0177-yDOI Listing

Belimumab slows organ damage progression.

Authors:
Jessica McHugh

Nat Rev Rheumatol 2019 Mar;15(3):126

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0176-zDOI Listing

Unmasking the double life of ELMO1.

Authors:
Joanna Collison

Nat Rev Rheumatol 2019 Mar;15(3):127

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0180-3DOI Listing

Treat-to-target in rheumatoid arthritis - are we there yet?

Nat Rev Rheumatol 2019 Mar;15(3):180-186

Amsterdam University Medical Centers, Amsterdam, Netherlands.

Treat-to-target has been established as a guiding principle for the treatment of rheumatoid arthritis (RA) and encompasses several distinct elements: choosing a target and a method for measuring it; assessing the target at a pre-specified time point; a commitment to change the therapy if the target is not achieved; and shared decision-making. A treat-to-target approach yields superior outcomes to standard care in RA, and the ACR, EULAR and other professional organizations have endorsed treat-to-target as a fundamental therapeutic strategy for RA. Nevertheless, data on the degree to which treat-to-target is employed in the clinic are scarce; it seems that although some elements of treat-to-target are widely used, full implementation remains uncommon. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41584-019-0170-5
Publisher Site
http://dx.doi.org/10.1038/s41584-019-0170-5DOI Listing
March 2019
14 Reads

GWAS cracks fracture risk.

Nat Rev Rheumatol 2019 Mar;15(3):126

Associate Editor Nature Communications, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0173-2DOI Listing
March 2019
4 Reads

Characterizing the autoreactive B cell transcriptome.

Authors:
Jeremy Sokolove

Nat Rev Rheumatol 2019 Mar;15(3):132-133

Division of Immunology and Rheumatology, VA Palo Alto Healthcare System and Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0169-yDOI Listing

How T cells lose FOXP3.

Nat Rev Rheumatol 2019 Mar;15(3):127

Nature Reviews Rheumatology, .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41584-019-0171-4DOI Listing
March 2019
3 Reads